IP Library › Granted Patent US 12,636,374
Granted Patent B2
US 12,636,374 · App. 17/824,293 · Granted May 26, 2026

Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Inventors: Annaliesa Sybil Anderson (Upper Saddle River, NJ); Caitlyn Gallagher (Ringwood, NJ); Jianxin Gu (Paramus, NJ); Isis Kanevsky (New York, NY); Jin-Hwan Kim (Suffern, NY); Justin Keith Moran (West Nyack, NY); Suddham Singh (Monroe, NY); Naveen Surendran (Dumont, NJ)
Assignee: Pfizer Inc.
A61K47/64A61K39/092A61K47/6415A61K47/646A61P31/04A61K2039/6031A61K2039/6037A61K2039/6068A61K2039/627
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,636,374
App. No.
17/824,293
Granted
May 26, 2026
Kind
B2
Abstract

The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.

Claims (24)

1 . An immunogenic glycoconjugate capable of inducing a humoral immune response to Streptococcus pneumoniae ( S. pneumoniae ) serotype 3 capsular polysaccharide comprising a S. pneumoniae serotype 3 capsular polysaccharide covalently conjugated to a carrier protein (CP) through a spacer and having the general formula:

wherein X is selected from the group consisting of CH 2 (CH 2 ) n′ , (CH 2 CH 2 O) m CH 2 CH 2 , NHCO(CH 2 ) n′ , NHCO(CH 2 CH 2 O) m CH 2 CH 2 , OCH 2 (CH 2 ) n′ and O(CH 2 CH 2 O) m CH 2 CH 2 ; where n′ is selected from 1 to 10 and m is selected from 1 to 4, and wherein X′ is selected from the group consisting of CH 2 O(CH 2 ) n″ CH 2 C═O and CH 2 O(CH 2 CH 2 O) m′ (CH 2 ) n″ CH 2 C═O, where n″ is selected from 0 to 10 and m′ is selected from 0 to 4, and

wherein said carrier protein is Cross-Reacting Material 197 (CRM197), C5a peptidase from Streptococcus (SCP), diphtheria toxoid (DT), tetanus toxoid (TT), or Haemophilus influenzae protein D (PD).

2 . The immunogenic glycoconjugate of claim 1 , wherein X is CH 2 (CH 2 ) n′ , where n′ is 2 and wherein X′ is CH 2 O(CH 2 ) n″ CH 2 C═O where n″ is 1.

3 . The immunogenic glycoconjugate of claim 2 , wherein said carrier protein is CRM 197 .

4 . The immunogenic glycoconjugate of claim 2 , wherein said carrier protein is SCP.

5 . The immunogenic glycoconjugate of claim 2 , wherein said carrier protein is TT.

6 . The immunogenic glycoconjugate of claim 1 , wherein the weight average molecular weight (Mw) of said polysaccharide before conjugation is between 75 kDa and 500 kDa.

7 . The immunogenic glycoconjugate of claim 6 , wherein the Mw of said polysaccharide before conjugation is between 100 kDa and 300 kDa.

8 . The immunogenic glycoconjugate of claim 7 , wherein the Mw of said polysaccharide before conjugation is between 100 kDa and 200 kDa.

9 . The immunogenic glycoconjugate of claim 1 , wherein the weight average molecular weight (Mw) of said glycoconjugate is between 500 kDa and 4,000 kDa.

10 . The immunogenic glycoconjugate of claim 1 , wherein the saccharide to protein ratio (SPR) of said glycoconjugate is 0.5 to 1.5.

11 . The immunogenic glycoconjugate of claim 1 , wherein the degree of conjugation of said glycoconjugate is 2 to 15.

12 . The immunogenic glycoconjugate of claim 1 , wherein said glycoconjugate comprises at least one covalent linkage between the carrier protein and the polysaccharide for every 5 to 10 saccharide repeat units of the polysaccharide.

13 . The immunogenic glycoconjugate of claim 1 , wherein said carrier protein is CRM 197 .

14 . The immunogenic glycoconjugate of claim 13 , wherein the Mw of said polysaccharide before conjugation is 100 kDa to 500 kDa, wherein the Mw of said glycoconjugate is 500 kDa to 4000 kDa, wherein SPR of said glycoconjugate is 0.5 to 1.5, wherein the degree of conjugation of said glycoconjugate is 2 to 15, and wherein said glycoconjugate comprises at least one covalent linkage between the carrier protein and the polysaccharide for every 5 to 10 saccharide repeat units of the polysaccharide.

15 . The glycoconjugate of claim 13 , wherein said glycoconjugate is a first glycoconjugate, and said first glycoconjugate elicits higher opsonophagocytic activity titers against S. pneumoniae serotype 3 capsular polysaccharide than a second glycoconjugate comprising a S. pneumoniae serotype 3 capsular polysaccharide covalently conjugated to the same type of carrier protein comprised by said first glycoconjugate, wherein the polysaccharide and carrier protein of said second glycoconjugate are conjugated by reductive amination.

16 . The immunogenic glycoconjugate of claim 1 , wherein said carrier protein is SCP.

17 . The immunogenic glycoconjugate of claim 16 , wherein the Mw of said polysaccharide before conjugation is 100 kDa to 500 kDa, wherein the Mw of said glycoconjugate is 500 kDa to 4000 kDa, wherein SPR of said glycoconjugate is 0.5 to 1.5, wherein the degree of conjugation of said glycoconjugate is 2 to 15, and wherein said glycoconjugate comprises at least one covalent linkage between the carrier protein and the polysaccharide for every 5 to 10 saccharide repeat units of the polysaccharide.

18 . The glycoconjugate of claim 16 , wherein said glycoconjugate is a first glycoconjugate, and said first glycoconjugate elicits higher opsonophagocytic activity titers against S. pneumoniae serotype 3 capsular polysaccharide than a second glycoconjugate comprising a S. pneumoniae serotype 3 capsular polysaccharide covalently conjugated to the same type of carrier protein comprised by said first glycoconjugate, wherein the polysaccharide and carrier protein of said second glycoconjugate are conjugated by reductive amination.

19 . The immunogenic glycoconjugate of claim 1 , wherein said carrier protein is TT.

20 . The immunogenic glycoconjugate of claim 19 , wherein the Mw of said polysaccharide before conjugation is 100 kDa to 500 kDa, wherein the Mw of said glycoconjugate is 500 kDa to 4000 kDa, wherein SPR of said glycoconjugate is 0.5 to 1.5, wherein the degree of conjugation of said glycoconjugate is 2 to 15, and wherein said glycoconjugate comprises at least one covalent linkage between the carrier protein and the polysaccharide for every 5 to 10 saccharide repeat units of the polysaccharide.

21 . The glycoconjugate of claim 19 , wherein said glycoconjugate is a first glycoconjugate, and said first glycoconjugate elicits higher opsonophagocytic activity titers against S. pneumoniae serotype 3 capsular polysaccharide than a second glycoconjugate comprising a S. pneumoniae serotype 3 capsular polysaccharide covalently conjugated to the same type of carrier protein comprised by said first glycoconjugate, wherein the polysaccharide and carrier protein of said second glycoconjugate are conjugated by reductive amination.

22 . The immunogenic glycoconjugate of claim 1 , wherein said carrier protein is DT or PD, wherein the Mw of said polysaccharide before conjugation is 100 kDa to 500 kDa, wherein the Mw of said glycoconjugate is 500 kDa to 4000 kDa, wherein SPR of said glycoconjugate is 0.5 to 1.5, wherein the degree of conjugation of said glycoconjugate is 2 to 15, and wherein said glycoconjugate comprises at least one covalent linkage between the carrier protein and the polysaccharide for every 5 to 10 saccharide repeat units of the polysaccharide.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →
Continuity (3)
Provisional Application 63228763 · Aug 3, 2021
Provisional Application 63194641 · May 28, 2021
Related Publication 20220387613A1 · Dec 8, 2022
References Cited (113)
US 4709017A · Collier et al. · 1987 [cited by applicant]
US 4950740A · Greenfield et al. · 1990 [cited by applicant]
US 5614382A · Metcalf · 1997 [cited by applicant]
US 5843711A · Collier et al. · 1998 [cited by applicant]
US 5917017A · Collier et al. · 1999 [cited by applicant]
US 6194388B1 · Krieg et al. · 2001 [cited by applicant]
US 6207646B1 · Krieg et al. · 2001 [cited by applicant]
US 6214806B1 · Krieg et al. · 2001 [cited by applicant]
US 6218371B1 · Krieg et al. · 2001 [cited by applicant]
US 6239116B1 · Krieg et al. · 2001 [cited by applicant]
US 6339068B1 · Krieg et al. · 2002 [cited by applicant]
US 6455673B1 · Collier · 2002 [cited by applicant]
US 8753645B2 · Biemans · 2014 [cited by examiner]
US 20060228380A1 · Hausdorff et al. · 2006 [cited by applicant]
US 20060228381A1 · Bahler et al. · 2006 [cited by applicant]
US 20070025398A1 · Yonge et al. · 2007 [cited by applicant]
US 20070184071A1 · Hausdorff et al. · 2007 [cited by applicant]
US 20070184072A1 · Hausdorff et al. · 2007 [cited by applicant]
US 20070231340A1 · Hausdorff et al. · 2007 [cited by applicant]
US 20080102498A1 · Bahler et al. · 2008 [cited by applicant]
US 20080268468A1 · Wong · 2008 [cited by examiner]
US 20150314007A1 · Satomaa · 2015 [cited by examiner]
US 20160346374A1 · Seeberger et al. · 2016 [cited by applicant]
US 20200054739A1 · Fairman et al. · 2020 [cited by applicant]
US 20200330579A1 · Forrest · 2020 [cited by examiner]
CA 2004810 · 1990 [cited by applicant]
CN 103495161 · 2014 [cited by applicant]
EP 0378881B1 · 1993 [cited by applicant]
EP 0427347B1 · 1995 [cited by applicant]
EP 0471177B1 · 1995 [cited by applicant]
EP 0594610B1 · 1998 [cited by applicant]
EP 0735898B1 · 1999 [cited by applicant]
EP 0761231B1 · 2000 [cited by applicant]
EP 0689454B1 · 2005 [cited by applicant]
WO 9101146A1 · 1991 [cited by applicant]
WO 9317712A2 · 1993 [cited by applicant]
WO 9403208A1 · 1994 [cited by applicant]
WO 9602555A1 · 1996 [cited by applicant]
WO 9701640A2 · 1997 [cited by applicant]
WO 9726008A1 · 1997 [cited by applicant]
WO 9818810A1 · 1998 [cited by applicant]
WO 9857659A1 · 1998 [cited by applicant]
WO 9858668A2 · 1998 [cited by applicant]
WO 9911241A1 · 1999 [cited by applicant]
WO 9952549A1 · 1999 [cited by applicant]
WO 0007621A2 · 2000 [cited by applicant]
WO 0023105A2 · 2000 [cited by applicant]
WO 0034487A1 · 2000 [cited by applicant]
WO 0037105A2 · 2000 [cited by applicant]
WO 0039299A2 · 2000 [cited by applicant]
WO 0056358A2 · 2000 [cited by applicant]
WO 0061761A2 · 2000 [cited by applicant]
WO 0062800A2 · 2000 [cited by applicant]
WO 0121152A1 · 2001 [cited by applicant]
WO 0121207A2 · 2001 [cited by applicant]
WO 0172337A1 · 2001 [cited by applicant]
WO 0198334A2 · 2001 [cited by applicant]
WO 02091998A2 · 2002 [cited by applicant]
WO 03024480A2 · 2003 [cited by applicant]
WO 03054007A2 · 2003 [cited by applicant]
WO 2004081515A2 · 2004 [cited by applicant]
WO 2004083251A2 · 2004 [cited by applicant]
WO 2006032499A1 · 2006 [cited by applicant]
WO 2007026190A2 · 2007 [cited by applicant]
WO 2008118752A2 · 2008 [cited by applicant]
WO 2009000826A1 · 2008 [cited by applicant]
WO 2010125480A1 · 2010 [cited by applicant]
WO 2014027302A1 · 2014 [cited by applicant]
WO 2014111344A1 · 2014 [cited by applicant]
WO 2015121783A1 · 2015 [cited by applicant]
WO 2017178664A1 · 2017 [cited by applicant]
Tiwari, V.K., Cu-Catalyzed Click Reaction in Carbohydrate Chemistry, Chemical Reviews (2016) 116(5), 3086-3240 (Year: 2016). [cited by examiner]
Anderson et al, “Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of Haemophilus influenzae type b”, The Journal of Pediatrics 107(3):346-351 (1985). [cited by applicant]
Baraldo et al, “N19 Polyepitope as a Carrier for Enhanced Immunogenicity and Protective Efficacy of Meningococcal Conjugate Vaccines”, Infection and Immunity 72(8):4884-4887 (2004). [cited by applicant]
Brown et al, “Structure of the [cited by applicant]
Crooke and Bennett, “Progress in Antisense Oligonucleotide Therapeutics”, Annu. Rev. Pharmacol. Toxicol. 36:107-129 (1996). [cited by applicant]
Douglas and Collier, “Exotoxin A of [cited by applicant]
Falugi et al., “Rationally designed strings of promiscuous CD4+ T cell epitopes provide help to Haemophilus Influenzae type b oligosaccharide: a model for new conjugate vaccines”, Eur. J. Immunol. 31:3816-3824 (2001). [cited by applicant]
Gatchalian et al, “A Randomized, Placebo-Controlled Study to Evaluate the Immunogenicity of an 11-Valent Pneumococcal Protein D Conjugate Vaccine Administered as Primary Vaccination to Infants at 6, 10 and 14 Weeks of A… [cited by applicant]
Geno et al, “Pneumococcal Capsules and Their Types: Past, Present, and Future”, Clinical Microbiology Reviews 28(3):871-899 (2015). [cited by applicant]
Goebel, “Studies on Antibacterial Immunity Induced by Artificial Antigens—I. Immunity to Experimental Pneumococcal Infection with an Antigen Containing Cellobiuronic Acid”, Journal of Experimental Medicine 69(3):353-364… [cited by applicant]
Hu et al, “Approach to Validating and Opsonophagocytic Assay for [cited by applicant]
Hunziker and Leumann, “Nucleic Acid Analogues: Synthesis and Properties”, Mod. Synth. Methods 7:331-417 (1995). [cited by applicant]
Insel and Anderson, “Oligosaccharide-Protein Conjugate Vaccines Induce and Prime for Oligoclonal IgG Antibody Responses to the Haemophilus influenzae b Capsular Polysaccharide in Human Infants”, J. Exp. Med. 163:262-269… [cited by applicant]
Kuo et al, “Characterization of a Recombinant Pneumolysin and Its Use as a Protein Carrier for Pneumococcal Type 18C Conjugate Vaccines”, Infection and Immunity 63(7):2706-2713 (1995). [cited by applicant]
Nurkka et al, “Immunogenicity and Safety of the Eleven Valent Pneumococcal Polysaccharide-Protein D Conjugate Vaccine in Infants”, Pediatr Infect Dis J 23:1008-1014 (2004). [cited by applicant]
Prymula et al, “Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both [cited by applicant]
Schneerson et al, “Serum Antibody Responses of Juvenile and Infant Rhesus Monkeys Injected with Haemophilus Influenzae Type b and Pneumococcus Type 6A Capsular Polysaccharide-Protein Conjugates”, Infection and Immunity … [cited by applicant]
Uchida et al, “Mutation in the Structural Gene for Diphtheria Toxin carried by Temperate Phage β”, Nature New Biology 233:8-11 (1971). [cited by applicant]
Uchida et al, “Diphtheria Toxin and Related Proteins—I. Isolation and Properties of Mutant Proteins Serologically Related to Diphtheria Toxin”, The Journal of Biological Chemistry 248(11):3838-3844 (1973). [cited by applicant]
Uhlmann and Peyman, “Antisense Oligonucleotides: A New Therapeutic Principle”, Chemical Reviews 90(4):543-584 (1990). [cited by applicant]
Miller et al, “Synthesis of Neoglycopeptides via Click Chemistry”, International Journal of Peptide Research and Therapeutics 16(3):125-132 (2010). [cited by applicant]
PCT International Search Report and Written Opinion for International Application No. PCT/IB2022/054914 mailed on Feb. 9, 2023. [cited by applicant]
Stefanetti et al, “Click chemistry compared to thiol chemistry for the synthesis of site-selective glycoconjugate vaccines using CRM197 as carrier protein”, Glycoconjugate Journal 37(5):611-622 (2020). [cited by applicant]
Macccalman, T., et al., “Glycoconjugate vaccines: some observations on carrier and production methods.”, Biotechnology and Genetic Engineering Reviews, 2019, 35(2):93-125. [cited by applicant]
Núñez-Villanueva, D., et al., “Cap control: cyclic versus linear oligomerisation in covalent template-directed synthesis.” RSC Advances, 2019, 9(51):29566-29569. [cited by applicant]
Pergolizzi, G., et al., “Contemporary glycoconjugation chemistry.”, Carbohydr. Chem., 2017, 42:1-46. [cited by applicant]
Hu, Q-Y., et al., Towards the next generation of biomedicines by site selective conjugation, Chem. Soc. Rev., 2016, 45, 1691. [cited by applicant]
Richichi, B., et al., Conjugation Techniques and Linker Strategies for Carbohydrate-Based Vaccines, Editor(s): Joseph J. Barchi, Comprehensive Glycoscience (Second Edition), Elsevier, 2021, pp. 676-705. [cited by applicant]
Hein, C.D., et al., Click Chemistry, a Powerful Tool for Pharmaceutical Sciences, Pharm Res. 25(10): 2216-2230 (2008). [cited by applicant]
Peeters, J.M., et al., Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates, J. Immunol. Meths. 120:133-143 (1989). [cited by applicant]
Bartoloni, A., et al., Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide, Vaccine 13(5):463-470 (1995). [cited by applicant]
Agrahari, A.K., et al., Cu(I)-Catalyzed Click Chemistry in Glycoscience and Their Diverse Applications, Chemical Reviews (2021) 121(13), 7638-7956. [cited by applicant]
Tiwari, V.K., Cu-Catalyzed Click Reaction in Carbohydrate Chemistry, Chemical Reviews (2016) 116(5), 3086-3240. [cited by applicant]
Wu, D, et al., Development of pneumococcal polysaccharide conjugate vaccine with long spacer arm, Vaccine 31 (2013) 5623-5626. [cited by applicant]
Wan, Q, et al., A Potentially Valuable Advance in the Synthesis of Carbohydrate-Based Anticancer Vaccines through Extended Cycloaddition Chemistry, J. Org. Chem. 2006, 71, 8244-8249. [cited by applicant]
Wan, Q, et al., A Potentially Valuable Advance in the Synthesis of Carbohydrate-Based Anticancer Vaccines through Extended Cycloaddition Chemistry, J. Org. Chem. 2006, 71, 8244-8249 (Supporting Information). [cited by applicant]
Krechikova O. I. et al., “Isolation, identification and antimicrobial susceptibility testing of [cited by applicant]
Buskas, T., et al., “The Immunogenicity of the Tumor-Associated Antigen Lewis May Be Suppressed by a Bifunctional Cross-Linker Required for Coupling to a Carrier Protein”, Chem. Eur. Journal, 2004, 10:3517-3524. [cited by applicant]
Costantino, P., et al., “The design of semi-synthetic and synthetic glycoconjugate vaccines”, Expert Opinion on Drug Discovery, 2011, 6(10):1045-1066. [cited by applicant]
Cox, A.D., et al., “Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: immunology of glycoconjugates with high carbohydrate loading”, Glycoconj Journal, 2010, 27:643-648. [cited by applicant]
Ju, T., et al., “The TN Antigen—Structural Simplicity and Biological Complexity”, Angewandte Chemie International Edition, 2011, 50:1770-1791. [cited by applicant]
Lipinski, T., et al., “A structurally diversified linker enhances the immune response to a small carbohydrate hapten”, Glycoconj Journal, 2011, 28:149-164. [cited by applicant]